Výsledky vyhledávání - "Anuraag R Kansal"

Akademický článek

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

Autor: Odette S Reifsnider, Anuraag R Kansal, Pranav K Gandhi, Lael Cragin, Sarah B Brand, Egon Pfarr, Kyle Fahrbach, Anastasia Ustyugova

Publikováno v: BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)

Introduction Empagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, is approved in the USA to reduce risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus (T2DM) and established CV disease, based on EMPA-REG OUTCOME

Externí odkaz: https://doaj.org/article/966d9585cb5946edb1ec8a1250454bac

Zobrazit plný text záznamu

Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial

Autor: Cheng Wang, Anuraag R. Kansal, Anastasia Ustyugova, Matthew Stargardter, Odette Reifsnider, Egon Pfarr, Christoph Wanner, Sarah Brand, Effie Kuti, Audrey Koitka-Weber

Publikováno v: American Journal of Kidney Diseases. 79:796-806

Rationale & Objective Benefits of sodium-glucose co-transporter 2 inhibitors on kidney outcomes have been demonstrated in clinical trials. Among patients with type 2 diabetes and established cardiovascular (CV) disease enrolled in EMPA-REG Outcome St

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c50d83db36b3fae1aba9c784f1235510
https://doi.org/10.1053/j.ajkd.2021.09.014

Zobrazit plný text záznamu

Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK

Autor: Allan Hackshaw, Karen C. Chung, Joshua J. Ofman, Heidi Reichert, Sarah S. Cohen, Anuraag R. Kansal

Publikováno v: British Journal of Cancer

Background Multi-cancer early detection (MCED) next-generation-sequencing blood tests represent a potential paradigm shift in screening. Methods We estimated the impact of screening in the US and UK. We used country-specific parameters for uptake, an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1716334025b67e66739b39276afaa544
https://doi.org/10.1038/s41416-021-01498-4

Zobrazit plný text záznamu

The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA

Autor: Ali Tafazzoli, Scott D. Ramsey, Alissa Shaul, Ameya Chavan, Weicheng Ye, Anuraag R. Kansal, Josh Ofman, A. Mark Fendrick

Publikováno v: PharmacoEconomics. 40(11)

Multi-cancer early detection (MCED) testing could increase detection of cancer at early stages, when survival outcomes are better and treatment costs are lower, but is expected to increase screening costs. This study modeled an MCED test for 19 solid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4479f5e938038e875acfb64d374c38b
https://pubmed.ncbi.nlm.nih.gov/36038710

Zobrazit plný text záznamu

Assessment of Medical and Public Assistance Expenditures and Employment Among US Adults With Cancer Diagnoses

Autor: David C. Grabowski, Anuraag R. Kansal, Dana P. Goldman, Darius N. Lakdawalla

Publikováno v: JAMA Network Open. 6:e2315823

ImportancePrior research suggests significant social value associated with increased longevity due to preventing and treating cancer. Other social costs associated with cancer, such as unemployment, public medical spending, and public assistance, may

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01d6a84b21f6312eb3ba59d0bac0fb3e
https://doi.org/10.1001/jamanetworkopen.2023.15823

Zobrazit plný text záznamu

Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States

Autor: Sarah Brand, Sharash Shetty, Odette Reifsnider, Anuraag R. Kansal, Valerie Aponte-Ribero, Pratik Pimple

Publikováno v: Diabetes, Obesity & Metabolism

Aim To estimate the cost‐effectiveness of sequential addition of empagliflozin versus sitagliptin after metformin in patients with type 2 diabetes (T2D) with or without cardiovascular disease (CVD) from the perspective of the US healthcare payer. M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1efffcd6ff7002ebdb15448a19685ed2
https://doi.org/10.1111/dom.14268

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání